Oragenics Files S-1/A Amendment for Securities Registration

TL;DR

ORGN filing S-1/A amendment, looks like they're prepping to sell more stock.

AI Summary

Oragenics, Inc. filed a pre-effective amendment (No. 2) to its Form S-1 registration statement on January 8, 2025, for the purpose of registering securities. The filing, with registration number 333-283927, indicates a potential offering of securities by the Florida-based pharmaceutical preparations company. Janet Huffman, CFO, is listed as an agent for service.

Why It Matters

This filing signals Oragenics' intent to potentially raise capital through a securities offering, which could impact its future operations and stock value.

Risk Assessment

Risk Level: medium — S-1/A filings indicate potential new stock offerings, which can be dilutive and introduce market uncertainty.

Key Numbers

• 333-283927 — Registration Number (Identifies this specific securities registration filing.)
• January 8, 2025 — Filing Date (Date the amendment was filed with the SEC.)

Key Players & Entities

• ORAGENICS INC (company) — Registrant
• 333-283927 (dollar_amount) — Registration Number
• January 8, 2025 (date) — Filing Date
• Janet Huffman (person) — Chief Financial Officer and Agent for Service
• Shumaker, Loop & Kendrick, LLP (company) — Legal Counsel
• ArentFox Schiff LLP (company) — Legal Counsel

FAQ

Key Financial Figures

• $0.001 — of one share of common stock, par value $0.001 per share (“Common Stock”)
• $0.33 — at an assumed public offering price of $0.33 per Unit, the last reported sale price
• $0 — d to the public in this offering, minus $0.001, and the exercise price of each Pre
• $0.339 — ncluding one Pre-Funded Warrant will be $0.339. (2) We will pay the Placement Agent
• $350,000 — cement agent fee, will be approximately $350,000. The delivery of the shares of Common
• $1,000,000 — acquisition, we paid Odyssey a total of $1,000,000 in cash, $500,000 of which was paid in
• $500,000 — Odyssey a total of $1,000,000 in cash, $500,000 of which was paid in October, 2023 and
• $6.9 billion — for concussion treatment was valued at $6.9 billion in 2020 and is forecast to reach $8.9 b
• $8.9 billion — illion in 2020 and is forecast to reach $8.9 billion by 2027, according to Grandview Researc

Filing Documents

• forms-1a.htm (S-1/A) — 930KB
• ex5-1.htm (EX-5.1) — 22KB
• ex23-1.htm (EX-23.1) — 5KB
• ex23-2.htm (EX-23.2) — 4KB
• ex107.htm (EX-FILING FEES) — 68KB
• forms-1_001.jpg (GRAPHIC) — 4KB
• forms-1_002.jpg (GRAPHIC) — 12KB
• ex5-1_001.jpg (GRAPHIC) — 21KB
• 0001493152-25-001268.txt ( ) — 1082KB

USE OF PROCEEDS

USE OF PROCEEDS 19 DIVIDEND POLICY 19 CAPITALIZATION 20

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 22

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 36

DESCRIPTION OF SECURITIES WE ARE OFFERING

DESCRIPTION OF SECURITIES WE ARE OFFERING 39 PLAN OF DISTRIBUTION 43 EXPERTS 46 LEGAL MATTERS 46 INCORPORATION BY REFERENCE 46 WHERE YOU CAN FIND MORE INFORMATION 48 ABOUT THIS PROSPECTUS We incorporate by reference important information into this prospectus. You may obtain the information incorporated by reference without charge by following the instructions under “Where You Can Find More Information.” You should carefully read this prospectus as well as additional information described under “Incorporation of Certain Information by Reference,” before deciding to invest in our securities. You should rely only on the information contained in this prospectus. We have not, and the Placement Agent has not, authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you, and we take no responsibility for any other information others may give you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the securities offered hereby, and only under circumstances and in jurisdictions where it is lawful to do so. We are not making an offer to sell these securities in any jurisdiction where an offer or sale is not permitted. The information contained in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since that date. The information incorporated by reference or provided in this prospectus contains statistical data and estimates, including those relating to market size and competitive position of the markets in which we participate, that we obtained from our o

View Full Filing

View this S-1/A filing on SEC EDGAR